A large drug company, Bristol Myers Squibb (BMS), has decided to buy a smaller company called Orbital Therapeutics for $1.5 billion. Orbital Therapeutics specializes in a type of therapy called CAR-T, which is a cutting-edge treatment that uses a patient’s own immune cells to fight cancer. By buying Orbital Therapeutics, BMS will gain access to several new treatments that use RNA, a molecule similar to DNA, to help the body fight diseases. This acquisition is expected to help BMS expand its range of treatments and stay competitive in the pharmaceutical industry.